SALT LAKE CITY, Utah, June 8, 2026
Seek Labs announced a major milestone in antiviral research with the completion of a comprehensive viral target atlas that maps CRISPR-addressable regions across all 25 viral families known to infect humans. Developed using the company’s AI-powered BioSeeker discovery platform, the atlas is designed to identify genetic vulnerabilities within viruses and support a more proactive approach to antiviral development. By creating a detailed map of conserved viral regions that are critical for pathogen survival, Seek Labs aims to help accelerate the discovery of new antiviral therapies against known viruses, emerging variants, and future outbreak threats.
BioSeeker Creates Comprehensive Viral Vulnerability Atlas
Traditional antiviral development often begins only after an outbreak emerges, leaving researchers racing to identify targets and develop treatments under urgent conditions. Seek Labs’ BioSeeker platform seeks to change this model by proactively mapping viral genomes before future outbreaks occur. The newly completed atlas identifies CRISPR-targetable regions across every known human-infecting viral family, creating a resource that may enable researchers to rapidly pinpoint therapeutic targets when new viral threats arise. The company believes this approach can reduce one of the earliest bottlenecks in outbreak response by providing pre-characterized genomic targets that can be evaluated immediately.
Supporting Next-Generation Antiviral Discovery
The viral target atlas is intended to support multiple stages of antiviral development. By analyzing viral sequences and identifying regions that cannot easily mutate without compromising viral function, BioSeeker can help prioritize high-value therapeutic targets. The platform is also designed to identify opportunities for multiplexed CRISPR guide strategies, which may reduce the risk of viral escape mutations. Seek Labs plans to use the atlas to prioritize viral families and specific pathogens for additional validation studies, including assessments of target accessibility, guide activity, effects on viral replication, and computational safety analyses. These efforts are expected to strengthen the company’s broader antiviral discovery pipeline.
Advertisement
AI-Powered Platform Expands Beyond Single-Pathogen Programs
According to Seek Labs, the milestone reinforces its strategy of operating as a platform-focused TechBio company rather than concentrating on a single disease program. The company highlighted recent examples such as Zaire ebolavirus, for which approved vaccines exist, and Bundibugyo virus, where limited countermeasure options remain available despite belonging to the same viral genus. By building a scalable discovery engine capable of identifying vulnerabilities across multiple viral families, Seek Labs hopes to support pathogen-specific, genus-level, and broader antiviral approaches that can adapt to evolving infectious disease threats. The company believes this strategy could provide a foundation for more durable and flexible therapeutic development in the future.
BioSeeker Powers Therapeutic and Diagnostic Innovation
At the center of Seek Labs’ technology platform is BioSeeker, an AI-driven system designed to analyze large volumes of genomic sequence data and identify regions that pathogens cannot readily mutate without losing essential biological function. These highly conserved regions may represent durable targets for both therapeutic and diagnostic applications. The platform continuously updates its models as new sequence information becomes available, providing a dynamic framework for sequence-directed discovery. Beyond antiviral development, BioSeeker supports the company’s broader initiatives in Sequence Ablation Therapeutics (SAT) and molecular diagnostics, creating an integrated ecosystem for translating genomic insights into real-world healthcare solutions.
Source: Seek Labs press release
